title: Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function.
abstract: BACKGROUND
  Atorvastatin and poly-unsaturated fatty acid (PUFA) are beneficial for lipid-modification, whether atorvastatin plus PUFA could confer better improvement on dyslipidemia and endothelium function is unknown.
  
  
  METHODS
  Dyslipidemia model of 40 rabbits were produced with atherogenic diet, and thereafter saline, atorvastatin, PUFA, or atorvastatin plus PUFA were prescribed for 1 week. Ten rabbits given normal diet served as the sham group. Parameters of interest including lipid profiles, endothelium function (nitric oxide, NO) and activation (solution vascular-cellular adhesion molecule, (sVCAM) and intracellular adhesion molecule, (sICAM)), markers of inflammation (C-reactive protein, CRP) and oxidation (malondialdehyde, MDA) were compared among groups.
  
  
  RESULTS
  There was no significant difference of parameters among groups at the initial. With 1 week of atherogenic diet administration, serum levels of lipid profiles, sVCAM and sICAM, CRP and MDA were significantly increased, accompanying with profound NO reduction, as compared to the sham group. After 1 week of medical intervention, as compared to the control group (saline administration), dyslipidemia and endothelium function were modestly improved with either atorvastatin or PUFA therapy. Nevertheless, these efficacies were further and significantly enhanced with combined therapy when compared to the control group (p<0.005), suggesting that there was synergistic effects of atorvastatin and PUFA co-therapy in rabbits with dyslipidemia.
  
  
  CONCLUSIONS
  Atorvastatin plus PUFA therapy could immediately contribute to better improvement of lipid-modification and endothelium function in rabbits with dyslipidemia.
authors.forename: Xianbing
authors.initials: X
authors.lastname: Song
authors.forename: Hongsheng
authors.initials: H
authors.lastname: Liu
authors.forename: Xiaotian
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Dongying People's Hospital, Shandong 257000, China. lzh186@yeah.net.
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Li
authors.forename: Congwu
authors.initials: C
authors.lastname: Huang
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D008297:Male; D009569:Nitric Oxide / Q000097:blood; D011758:Pyrroles / Q000008:administration & dosage*; D011817:Rabbits
chemical_list: D000924:Anticholesteremic Agents; D005231:Fatty Acids, Unsaturated; D006538:Heptanoic Acids; D011758:Pyrroles; D009569:Nitric Oxide; D000069059:Atorvastatin